Glox Therapeutics

Glox Therapeutics is an Oxford and Glasgow-based biotechnology company that develops precision antibiotics using engineered bacteriocins to treat severe infections caused by antimicrobial-resistant Gram-negative bacteria. The firm focuses on creating narrow-spectrum therapies targeting specific drug-resistant pathogens, such as Pseudomonas aeruginosa and Escherichia coli, without damaging the broader human microbiome. To address a global health crisis responsible for approximately 1.27 million annual deaths, the enterprise has raised £4.3 million in seed funding co-led by the Boehringer Ingelheim Venture Fund and Scottish Enterprise. Additionally, the organization secured a £1 million grant from the Pathways to Antimicrobial Clinical Efficacy (PACE) programme to further accelerate its therapeutic development pipeline. Built upon over two decades of academic research as a spin-out from the Universities of Oxford and Glasgow, Glox Therapeutics was founded in 2023 by Colin Kleanthous and Daniel Walker.